The GH combination raises IGF-1 (anabolic signaling, tissue, grow and renew), BPC-157 provides local regenerative capacity
Gradual progression respecting body signals
BPC 157 promotes the repair of skin and other tissues after injury by supporting signals that tell cells to grow and repair themselves
GLP-1 and GIP receptor agonists have a low intrinsic risk of causing hypoglycaemia when used alone, because their insulin-stimulating effects are glucose-dependent
Chronic conditions show gradual improvement
Molecular pathways documented in preclinical research include: (1) activation of nitric oxide (NO) synthesis via L-arginine/eNOS pathway, (2) transcriptional upregulation of VEGF-A and FGF-2 favouring angiogenesis, (3) modulation of the Egr-1 early transcription factor involved in fibroblast proliferation, (4) interaction with 5-HT2A and dopaminergic receptors in some behavioural models, (5) stabilisation of endothelial function via eNOS modulation and reduction of oxidative stress (8-OH-dG, MDA)